Retatrutide: A GIP/GLP-1/Glucagon Triple Receptor Agonist

Research summary. Retatrutide (development code LY3437943) is a synthetic peptide engineered as a unimolecular triple receptor agonist at the gastric inhibitory polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Developed by Eli Lilly, it represents the next progression in the multi-receptor incretin agonist class beyond tirzepatide (which engages GIP and GLP-1 only). As of mid-2026, retatrutide is in Phase 3 clinical investigation for obesity and related metabolic indications.

(Note: this catalogue uses the label "Retatrutide-GLP3" for organisational reasons. There is no formal endogenous peptide called "GLP-3"; the catalogue is using the term to indicate retatrutide's third receptor target — the glucagon receptor.)

Molecular profile

• Class: Long-acting GIP/GLP-1/glucagon triple receptor agonist
• Length: 39-amino-acid synthetic peptide
• Modification: Fatty-acid acylation linker for albumin binding and once-weekly dosing
• Molecular formula: C₁₇₉H₂₈₈N₅₀O₅₂
• Molecular weight: ~3998.6 g/mol
• Synonyms: LY3437943
• Half-life: Approximately 6 days, supporting once-weekly subcutaneous administration

The molecule is engineered from a GIP/glucagon hybrid backbone with substitutions that generate cross-reactivity with the GLP-1 receptor while preserving activity at GIP and glucagon receptors. The relative potencies at the three receptors are not equal — retatrutide displays its highest activity at GIPR and GLP-1R with somewhat reduced activity at GCGR — but all three pathways are engaged at clinically relevant exposures.

Mechanism of action

Retatrutide engages three complementary receptor systems:

GLP-1R engagement drives the established incretin profile: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central satiety signalling.

GIPR engagement contributes adipose-tissue effects, adiponectin elevation, and additional CNS effects on feeding circuits, paralleling tirzepatide's pharmacology.

GCGR engagement introduces a novel layer not present in either tirzepatide or single-receptor GLP-1R agonists. Glucagon receptor activation drives:

• Increased hepatic glucose output — counterbalanced by GLP-1R-driven insulin secretion to maintain glycaemic control
• Increased energy expenditure through hepatic and adipose-tissue effects, including upregulation of lipolysis and thermogenic programmes
• Reduced hepatic lipid accumulation, with potential utility in non-alcoholic fatty liver disease research
• Modulation of cholesterol metabolism

The therapeutic logic is that GLP-1-mediated insulin secretion can offset the hyperglycaemic potential of GCGR engagement, while GCGR engagement adds an energy-expenditure component absent from pure incretin pharmacology. The result, in clinical practice, is greater weight loss than achieved by GIP/GLP-1 dual agonism alone.

Clinical research highlights

Phase 2 obesity trial. A landmark Phase 2 study reported by Jastreboff and colleagues in 2023 evaluated retatrutide in adults with obesity over 48 weeks. Mean body-weight reductions reached approximately 24% at the 12 mg dose — exceeding the magnitude reported with tirzepatide in comparable studies and approaching the weight loss achieved by bariatric surgery in some patient populations [1]. The trial was widely interpreted as a major advance in obesity pharmacotherapy.

Phase 2 type 2 diabetes trial. Rosenstock and colleagues reported a Phase 2 study of retatrutide in adults with type 2 diabetes, demonstrating substantial HbA1c reductions and weight loss alongside acceptable tolerability [2].

Phase 2 NAFLD trial. A Phase 2 study in adults with metabolic-dysfunction-associated steatotic liver disease (MASLD/NAFLD) reported substantial reductions in liver fat content as measured by MRI, consistent with the predicted contribution of GCGR engagement to hepatic lipid handling.

Phase 3 programme (ongoing). Retatrutide entered Phase 3 development under the TRIUMPH programme series, including TRIUMPH-1 through TRIUMPH-4 trials examining obesity, type 2 diabetes, NAFLD, and obstructive sleep apnoea. Reported topline results have been positive but full Phase 3 reporting and regulatory review continue.

Why a triple agonist

The conceptual progression from single-receptor to multi-receptor incretin agonists reflects an increasingly mechanistic approach to obesity and metabolic disease. Each receptor adds a different physiological lever:

• GLP-1R: Satiety and glucose-dependent insulin
• GIPR: Adipose effects and adiponectin
• GCGR: Energy expenditure and hepatic lipid handling

The triple agonist hypothesis — that engaging all three pathways produces more substantial weight loss than engaging any subset — has been substantiated by Phase 2 data showing weight reductions exceeding those of established dual agonists. The trade-offs, however, include greater complexity in dose-response calibration (because GCGR activation must be balanced against GLP-1R-driven insulin secretion to avoid hyperglycaemia or hypoglycaemia) and the potential for distinctive tolerability profiles relative to dual agonists.

Position in the landscape

Retatrutide sits at the cutting edge of the multi-receptor incretin class as of 2026:

• Single-target GLP-1R agonists: semaglutide, liraglutide
• Dual-target GIP/GLP-1: tirzepatide
• Dual-target GLP-1/GCGR: survodutide, cotadutide, pemvidutide
• Triple-target GIP/GLP-1/GCGR: retatrutide (and emerging molecules from other developers)
• Multi-receptor with GIPR antagonism: maridebart cafraglutide (GLP-1R agonist + GIPR antagonist)

Current status

Retatrutide is in Phase 3 clinical development and has not received marketing authorisation. The molecule is not approved as a therapeutic in any jurisdiction at the time of writing. Reported Phase 2 data are encouraging but do not constitute regulatory approval, and definitive efficacy and safety conclusions await Phase 3 completion and regulatory review.

Key takeaways for researchers

• Retatrutide is a unimolecular triple agonist at GIP, GLP-1, and glucagon receptors.
• Each receptor contributes a complementary metabolic effect; GCGR engagement adds an energy-expenditure component absent from dual agonists.
• Phase 2 data report ~24% mean body weight reduction at the highest tested dose in adults with obesity.
• Phase 3 development is ongoing across obesity, type 2 diabetes, NAFLD, and OSA indications.
• Retatrutide is not approved as a therapeutic at the time of writing.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526.
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529–544.

---

This article is provided for educational and research purposes only. Retatrutide is an investigational research peptide currently in Phase 3 clinical development. It has not received marketing authorisation by the U.S. FDA or any other major regulatory authority and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition outside the context of authorised clinical trials. All research work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.